Thrombolytic Treatment in Stroke: A Focus on the Salvageable Brain Tissue

Schwamm LH Koroshetz WJ Sorensen AG . Time course of lesion development in patients with acute stroke: serial diffusion- and hemodynamic-weighted magnetic resonance imaging. Stroke 1998;29:2268–76.

Ay H Koroshetz WJ Buonanno FS . Negative Diffusion-Weighted MR Imaging with Stroke-Like Focal Deficits. Neurology, 1999;51:1369–1376.

Parsons MW Barber PA Chalk J . Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol. 2002 Jan;51:28–37.

Furlan A Higashida R Wechsler L . Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial. JAMA 1999;282: 2003–2011.

NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.

Katzan IL Furlan AJ Lloyd LE . Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151–8.

Hacke W Kaste M Fieschi C . Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.

Clark WM Wissman S Albers GW . Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019–26.

Hacke W Kaste M Fieschi C . Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245–1251.

Pessin M del Zoppo GJ Furlan AJ . Thrombolytic treatment in acute stroke: review and update of selective topics. In: Cerebrovascular diseases. 19^th Princeton Stroke Conference. Moskowitz MA Caplan LR (editors). Boston: Butterworth-Heinemann; 1995. pp. 409–418).

International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischemic stroke. Lancet 1997;349:1569–1581.